|
Poly swap, unknown reason.Due to the original poly part and lot number remaining unknown, simulated use testing cannot be conducted utilizing similar parts to simulate the event.Additionally, the poly component was implanted for an unknown amount of time, so simulated use testing would not be able to accurately recreate the physiological changes that occurred during implantation.There were 47 similar complaints identified for star poly swaps with no indication of poly damage.Previous complaints were investigated and documented by stryker prior to february 2023 and do not aid in investigation for this complaint.Similar complaints identified after february 2023 do not aid in the investigation for this complaint as the part and lot numbers remain unknown.Ohr review was not conducted due to the complaint part not being returned and the lot number remaining unknown.It is unknown if the doctor followed the surgical technique with the limited information available regarding the original implantation.The poly was not returned to the houston site, so visual and dimensional inspection did not occur.Simulated use testing did not occur.Due to the original component part and lot number remaining unknown and the device not being returned, the root cause shall remain as unknown.The following information remains unknown: - date implanted, - patient height, - patient weight, - patient bone quality, - patient activity leval, - non complaince, - patient co-morbidities, - inventory type, - part and lot number.Information not provided is not available to the reporter.Thus, good faith effort was achieved.The overall risk is high with a risk index of 3.Severity level of 4 (significant) is appropriate as there could be permanent functional impairment of body function and the failure may occur with or without warning.It is to be noted that no adverse events were reported resulting from the swapped poly.It was determined that (b)(4) tibial polymer components (pn:400-14x) were sold between december 2022 and december 2023.With 48 reported events, the occurrence rate is (b)(4).Thus, an occurrence level of 5 (frequenuhigh) is appropriate.Per (b)(4) revision 3 risk benefit analysis for (b)(4), "every endoprosthesis has a limited lifespan.With state of the art techniques, there is no potential for further mitigation of the risks from a clinical point of view".Therefore, the risk shall remain appropriate.Though the root cause remains unknown, it is not expected to be attributed to the supplier.
|